Harvard Bioscience (HBIO) Retained Earnings (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Retained Earnings data on file, last reported at -$12.3 million in Q1 2026.

• Retained Earnings for Q1 2026 came in at -$12.3 million, up 14.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.3 million (up 14.26% YoY), and the FY2025 annual result was -$214.7 million, down 35.88% from the prior year.
• Retained Earnings climbed to -$12.3 million in Q1 2026 per HBIO's latest filing, from -$214.7 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$12.3 million in Q1 2026 and troughed at -$214.7 million in Q4 2025.
• A 5-year average of -$90.9 million and a median of -$137.1 million in 2022 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings plunged 1318.07% in 2022, then jumped 90.92% in 2024.
• A 5-year view of Retained Earnings shows it stood at -$142.2 million in 2022, then dropped by 2.4% to -$145.6 million in 2023, then slipped by 8.52% to -$158.0 million in 2024, then plunged by 35.88% to -$214.7 million in 2025, then surged by 94.27% to -$12.3 million in 2026.
• Business Quant data shows HBIO's Retained Earnings at -$12.3 million in Q1 2026, -$214.7 million in Q4 2025, and -$12.4 million in Q3 2025.